Conditions: Myelodysplastic Syndromes Blood Disease Bone Marrow Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 22
Healthy volunteers: no

Brief summary:
This study is to evaluate the efficacy, safety and tolerability of vorinostat in patients with lower risk Myelodysplastic Syndrome (MDS).

Detailed description:

Arms:
arm 1: vorinostat 400 mg arm 2: vorinostat 200 mg

Interventions: intervention 1: vorinostat intervention 2: vorinostat
Intervention descriptions: intervention 1: vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles. intervention 2: vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.

Protocol document: